
Read & Publish Open Access initiative



Biology Open



Biology Open was launched in 2012 as the first fully Open Access journal published by The Company of Biologists. It publishes rigorously conducted research that spans the breadth of the biological and biomedical sciences.



From adenovirus to zebrafish, via cancer biology and stem cells, the Biology Open team is committed to Open Access publishing as a mechanism to widen access, promote equality and ensure sustainability in publishing in the biological sciences.

Biology Open aims to support early-career researchers in particular. It publishes **First Person interviews** with the first authors of research papers, and creates career development opportunities through its early-career researcher focused **Meeting Reviews** and **Future Leader Reviews** initiative.

Readership

Biology Open is read by scientists at all career levels and from a broad field of expertise – including plant and animal biologists, geneticists, molecular biologists, cell biologists, and stem cell and developmental biologists, as well as scientists who study molecular, cellular and organismal physiology. Content is freely available to the journal's communities of researchers and the general public.

Abstracting and indexing services

Biology Open is abstracted and/or indexed by (amongst others): Biological Abstracts, BIOSIS, CAB abstracts, Chemical Abstracts, Clarivate Analytics Web of Science, Medline, PMC, PubMed, Scopus and the Directory of Open Access Journals (DOAJ).

Open Access commitment

BiO was the first fully Open Access journal launched by The Company of Biologists. It has been awarded the Directory of Open Access Journals seal – given to journals that achieve a high level of openness, adhere to best practice and high publishing standards. The Company has a long-standing commitment to Open Access, and our hybrid journals were the first in the world to be awarded Transformative Journal status by Plan S. All our journals are included in our Read & Publish Open Access agreements.

Key metrics

- 2022 Impact Factor: 2.4
- Five-year Impact Factor: 2.3
- Two-year citation median: 2.0
- Eigenfactor score: 0.00554
- Article Influence Score: 0.681
- Immediacy Index: 0.6
- h-index: 52
- Scopus: 4.7
- SJR indicator: 0.824
- SNIP: 0.657



Biology Open

Available through The Company of Biologists' Read & Publish Open Access initiative



Expert team of academic editors

Editor-in-Chief

• Daniel Gorelick (Baylor College of Medicine, Houston, USA)

Deputy Editors

- Catherine L. Jackson (Institut Jacques Monod, Paris, France)
- Tristan Rodríguez (Imperial College London, UK)

Editors


- Alissa Armstrong (University of South Carolina, USA)
- Kendra J. Greenlee (North Dakota State University, USA)
- Lewis Halsey (University of Roehampton, London, UK)
- Christopher A. Maher (Washington University School of Medicine, USA)
- Lauren Nadler (The University of Southampton, UK)
- Luca Scorrano (University of Padua, Italy)

What are the benefits of Read & Publish agreements?

- Uncapped fee-free Open Access publishing of research articles in all our journals: Development, Journal of Cell Science, Journal of Experimental Biology, Disease Models & Mechanisms and Biology Open
- Unlimited "read" access to our three hybrid journals (Development, Journal of Cell Science and Journal of Experimental Biology) and their archives
- · Transparent cost-neutral pricing
- · Single annual fee covers reading and publishing
- Easy to switch from a subscription to a Read & Publish agreement
- · Compliant with funder mandates including Plan S

Well done to The Company of Biologists for their excellent Read & Publish deals, including with my institution, St George's, University of London. It's a great pleasure and benefit for our paper in Biology Open to be immediately available to all, free of charge.

Professor Dorothy C. Bennett, St. George's, University of London, UK



Figures based on the latest available data from Impact Vizor and Altmetric Explorer

